Lymph Node-Targeted P2X7R Antagonist Treatment for Hyperinflammation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for hyperinflammatory syndrome, such as those targeting the P2X7 receptor (P2X7R), face challenges due to the need for systemic administration that exceeds the maximal tolerable plasma levels, leading to undesirable side effects and ineffective treatment of hyperinflammation.

Innovation Solution

Administering a P2X7R antagonist directly to lymph nodes at concentrations above the maximal tolerable plasma level, utilizing topical or invasive routes to achieve effective receptor inhibition without systemic elevation, thereby inducing clonal expansion of anti-inflammatory T-regulatory cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If a P2X7R antagonist is administered systemically to achieve effective receptor inhibition, then hyperinflammation is treated, but plasma levels exceed the maximal tolerable level causing undesirable side effects

Engineering Contradiction:

Improveeffectiveness of hyperinflammation treatmentVSAvoidundesirable side effects from toxic plasma levels

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention segments the administration approach by targeting lymph nodes specifically rather than systemic administration. This localizes the drug delivery to the primary site where P2X7R antagonism is needed for hyperinflammation treatment, avoiding widespread distribution to other organs and tissues where toxic effects would occur.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The invention applies local quality by creating a high concentration of P2X7R antagonist specifically in lymph nodes while maintaining low or absent concentrations in plasma and other systemic compartments. This spatial differentiation of drug concentration allows effective receptor inhibition at the target site without exposing other systems to toxic levels.

Inventive Principle:

Principle #3Local quality

2Quantity of substance

If a P2X7R antagonist is administered at high plasma levels to ensure sufficient receptor inhibition, then P2X7Rs are effectively blocked, but toxic side effects occur

Engineering Contradiction:

Improveconcentration of P2X7R antagonistVSAvoidtoxic plasma levels

Core Design Contradiction:

Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The invention segments the distribution of the P2X7R antagonist into compartmentalized concentrations: high concentration in lymph nodes (therapeutic compartment) and low/zero concentration in plasma (systemic compartment). This segmentation allows achieving the required quantity of substance at the target site without the harmful effects of high systemic levels.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The invention uses lymph nodes as an intermediary target organ that mediates the therapeutic effect. By delivering the antagonist directly to lymph nodes where P2X7R activation drives hyperinflammation, the drug achieves its effect through this intermediary site rather than requiring high plasma levels, thus avoiding toxicity while maintaining efficacy.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS12419848B2Treatment of hyperinflammatory syndrome

Publication Date: 2025.09.23 REMICINE IP BV

AI summary

Described is an antagonist of a mammalian P2X7R for use in the treatment of a hyperinflammatory syndrome in a mammalian patient, by primary lymph node targeted administration of the said P2X7R antagonist in the said patient to a concentration in the said targeted lymph nodes that is above the maximal tolerable plasma level of the said antagonist in the said mammal.